3 completed, 2 withdrawn. 5 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 3, Withdrawn 2 |
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
Follow Auranofin: new trials by email Literature Review of Auranofin trials Research Report on Auranofin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma Temozolomide, Aprepitant, Minocycline - Glioblastoma | Phase 1 / Phase 2 | Completed | University of Ulm | 10 | 2016-11-01 | 2021-10-05 |
| Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer Auranofin, Sirolimus, Laboratory Biomarker Analysis - Extensive Stage Small Cell Lung Carcinoma, Lung Adenocarcinoma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 29 | 2014-05-14 | 2025-09-05 |
| Auranofin PK Following Oral Dose Administration Auranofin - Amoebiasis | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 15 | 2014-04-02 | 2017-04-28 |
| Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer auranofin, sirolimus, laboratory biomarker analysis - Recurrent Non-small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Withdrawn | Mayo Clinic | 2013-08-01 | 2016-08-26 | |
| Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection Auranofin - HIV | Phase 1 / Phase 2 | Withdrawn | Vaccine and Gene Therapy Institute, Florida | 2015-02-26 |
Carcinoma, Non-Small-Cell Lung (2) · Adenocarcinoma of Lung (1) · Amebiasis (1) · Glioblastoma (1) · Small Cell Lung Carcinoma (1)
Mayo Clinic (2) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · University of Ulm (1) · Vaccine and Gene Therapy Institute, Florida (1)
United States (4) · Germany (1)
Marc-Eric Halatsch, MD (1) · Michael E Menefee, M.D. (1) · Patrick D Yeramian, MD (1) · Yanyan Lou, M.D., Ph.D. (1)
PMID 27821451, PMID 34620071, PMID 34959641, PMID 35254001, PMID 38396172, PMID 41114938
P30CA015083 (1), R21CA153000 (1)